SCHEMBL4922355

SCHEMBL4922355

Cc1ccc(-c2c(C(=O)O)[nH]c3ccc(NS(=O)(=O)c4ccc(C(C)(C)C)cc4)cc23)cc1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.50
SERPINE1 P05121 1/20 0.48
PTPN5 P54829 1/20 0.47
PKM P14618 2/20 0.46
MAPT P10636 3/20 0.45
TP53 P04637 2/20 0.45
LMNA P02545 1/20 0.45
MEN1 O00255 5/20 0.43
KMT2A Q03164 5/20 0.43
ALDH1A1 P00352 2/20 0.43
CYP1A2 P05177 1/20 0.43
POLB P06746 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
GAA P10253 3/20 0.43
GFER P55789 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
HIF1A Q16665 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4927088 0.89 BRD4 (0.50) BRD4SERPINE1PTPN5MAPTMEN1
SCHEMBL3946651 0.89 BRD4 (0.53) BRD4SERPINE1PTPN5MAPTMEN1
SCHEMBL3947323 0.88 BRD4 (0.54) BRD4SERPINE1PTPN5MAPTMEN1
SCHEMBL4926342 0.87 BRD4 (0.52) BRD4SERPINE1PTPN5MAPTLMNA
SCHEMBL3950142 0.86 BRD4 (0.53) BRD4SERPINE1PTPN5MAPTMEN1
SCHEMBL4930867 0.86 UQCRB (0.56) BRD4SERPINE1PTPN5PKMMAPT
SCHEMBL3945167 0.86 BRD4 (0.61) BRD4SERPINE1PTPN5MAPTMEN1
SCHEMBL3945225 0.85 BRD4 (0.54) BRD4SERPINE1PTPN5MAPTMEN1
SCHEMBL4933597 0.85 GPR35 (0.53) BRD4SERPINE1PTPN5MAPTMEN1
SCHEMBL4933945 0.84 MAPT (0.59) BRD4SERPINE1PTPN5MAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060074084-A1 Inhibitors of soluble adenylate cyclase BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2006-04-06 US claimed
US-20080004268-A1 INHIBITORS OF SOLUBLE ADENYLATE CYCLASE NGUYEN DUY 2008-01-03 US disclosed
US-20060074084-A1 Inhibitors of soluble adenylate cyclase BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2006-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004268-A1 INHIBITORS OF SOLUBLE ADENYLATE CYCLASE ADCY1, ADCY2, ADCY5 BRD4 3928/4885SERPINE1 688/4885PTPN5 1567/4885
US-20060074084-A1 Inhibitors of soluble adenylate cyclase ADCY1, ADCY2, ADCY5 BRD4 3928/4885SERPINE1 688/4885PTPN5 1567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.